 Cyclophosphamide
"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 0 | 1 | 1 | | 1987 | 0 | 2 | 2 | | 1988 | 2 | 1 | 3 | | 1992 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 2 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 3 | 3 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 5 | 7 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
García-Cadenas I, Yáñez L, Jarque I, Martino R, Pérez-Simón JA, Valcárcel D, Sanz J, Bermúdez A, Muñoz C, Calderón-Cabrera C, García E, Alonso L, Suárez-Lledó M, González Vicent M, Heras I, Viguria MC, Batlle M, Vázquez L, López J, Solano C. Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH). Eur J Haematol. 2019 Jun; 102(6):465-471.
-
Reddy SV, Payne S, Schaal S. Angiographically Silent Macular Edema. JAMA Ophthalmol. 2016 Apr; 134(4):453-4.
-
Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. 2015 Sep; 90(9):778-83.
-
McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i123-31.
-
Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8.
-
Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10; 32(32):3651-8.
-
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-7.
-
Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I, García-Ramírez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jiménez R, Martínez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, Majeti R, Melnick A, Cobaleda C, Alizadeh AA, Sánchez-García I. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun. 2014 Jun 02; 5:3904.
-
Joy MS, Roberts BV, Wang J, Hu Y, Hogan SL, Falk RJ. A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis. Int J Clin Pharmacol Ther. 2014 Apr; 52(4):303-13.
-
Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol. 2014 May; 9(5):905-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|